Catalog No.
Product Name
Application
Product Information
Citations
-
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-amino-PEG5-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate featuring Pomalidomide as the cereblon ligand. This compound effectively engages the ubiquitin-proteasome system to promote targeted protein degradation via PROTAC technology. It is suitable for applications in cancer research and therapeutic development, enabling the study of protein modulation pathways and the exploration of novel treatment strategies. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-3-methylbutanyl acetate-methanesulfonothioate-PEG3-NH2 TFA is an E3 ligase ligand-linker conjugate designed for use in PROTAC (Proteolysis Targeting Chimeras) applications. This compound features the (S,R,S)-AHPC ligand along with a three-unit PEG linker, facilitating targeted protein degradation through the ubiquitin-proteasome system. It is suitable for studies involving E3 ligase modulation and the development of novel therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-amino-PEG4-NH2 is a synthetic E3 ligase ligand-linker conjugate that features a Pomalidomide-derived cereblon ligand coupled with a PEG4 linker. This compound is designed to facilitate targeted protein degradation through the PROTAC (proteolysis-targeting chimera) technology. It is useful for exploring E3 ligase-mediated degradation pathways and can be applied in drug discovery and development, particularly in the context of cancer research and therapeutics. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-PEG1-NH2 is an E3 ligase ligand-linker conjugate that incorporates the VH032-derived VHL ligand along with a PEG1 linker. This compound is designed for use in PROTAC (PROteolysis TArgeting Chimeras) technology, facilitating targeted protein degradation in research applications. Its unique design enables the selective recruitment of E3 ligases, making it a valuable tool for studying protein regulation and degradation pathways. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide-C5-amido-Boc is a Cereblon ligand designed for the recruitment of the CRBN protein, targeting E3 ligase-mediated protein degradation pathways. This compound can be conjugated to various ligands via a spacer to produce PROTACs (proteolysis targeting chimeras), facilitating the selective degradation of specific proteins. Its application in research includes studying targeted protein elimination and elucidating protein function in various biological contexts. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-PEG3-acid is an E3 ubiquitin ligase ligand-linker conjugate designed for the synthesis of proteolysis-targeting chimeras (PROTACs). This compound facilitates the recruitment of target proteins to the ubiquitin-proteasome system, enabling selective degradation of unwanted proteins in cellular contexts. It is a valuable reagent for researchers investigating targeted protein degradation and its applications in cancer therapeutics and other diseases. -
Ligand for E3 Ligase
Pomalidomide-PEG5-C2-NH2 hydrochloride is a Pomalidomide derivative functioning as a ligand for cereblon (CRBN), facilitating the recruitment of the CRBN protein. This compound is instrumental in the design of proteolysis-targeting chimeras (PROTACs) through its conjugation with other proteins via a linker. Its applications extend to targeted protein degradation studies and the exploration of CRBN-mediated pathways in cellular models. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-C7-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that aids in the development of targeted protein degraders. This compound facilitates the synthesis of PROTACs (Proteolysis Targeting Chimeras), enabling selective degradation of specific proteins within cellular systems. Its unique structure supports targeted intracellular delivery and engagement with E3 ubiquitin ligases, making it a valuable reagent for research focused on protein modulation and therapeutic applications. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-5-PEG3-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that combines a thalidomide-derived cereblon ligand with a polyethylene glycol (PEG) linker. This compound facilitates the recruitment of target proteins to the E3 ligase, enhancing targeted protein degradation via PROTAC (Proteolysis Targeting Chimera) technology. It serves as a valuable tool for research in protein modulation, cellular signaling pathways, and therapeutic development in oncology and other diseases. -
E3 Ligase Ligand-Linker Conjugate
Phthalimidinoglutarimide-6-piperazine is an E3 ubiquitin ligase ligand-linker conjugate designed for the synthesis of complete Proteolysis Targeting Chimeras (PROTACs). This compound facilitates targeted protein degradation by engaging the ubiquitin-proteasome system, making it a valuable tool in drug discovery and cellular biology research. Its applications include probing E3 ligase functionality and investigating the therapeutic potential of protein modulation. -
E3 Ligase Ligand-Linker Conjugates
Glutarimide-Isoindolinone-NH-PEG4-COOH is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound features a cereblon ligand that facilitates the recruitment of E3 ligases, promoting ubiquitination of target proteins. Its unique PEG4 linker enhances solubility and stability, making it suitable for use in PROTAC technology and related research endeavors in protein regulation and therapeutic development. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-C1-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate designed for targeted protein degradation through PROTAC technology. This compound features the (S,R,S)-AHPC moiety, which serves as a VHL ligand, facilitating selective interactions with E3 ligases. Its application in research enables studies on protein ubiquitination and regulation, contributing to advancements in therapeutic development and cellular biology. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-5-PEG4-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that combines a Thalidomide-derived cereblon ligand with a polyethylene glycol (PEG) linker. This compound is integral to the development of PROTAC (Proteolysis Targeting Chimera) technology, facilitating targeted protein degradation in cellular systems. Thalidomide-5-PEG4-NH2 hydrochloride is valuable in drug discovery and therapeutic research, enabling the selective modulation of protein levels for various biological studies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-PEG4-C2-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that features a Thalidomide-derived cereblon ligand coupled with a PEG4 linker. This compound is designed to facilitate targeted protein degradation through the PROTAC (PROteolysis TArgeting Chimeras) technology. Its unique structure allows for the selective modulation of protein levels, making it a valuable tool for research in cellular biology and drug development. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-C12-NH2 hydrochloride is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound functions as a Cereblon-based degrader for KRAS G12C, facilitating the selective degradation of this oncogenic protein. It is suitable for research into innovative therapeutic strategies for KRAS-driven cancers and offers insights into the development of PROTAC technology in cancer treatment. -
E3 Ligase Ligand-Linker Conjugates
Glutarimide-Isoindolinone-NH-PEG3-COOH is an E3 ligase ligand-linker conjugate that features a cereblon ligand combined with a polyethylene glycol (PEG) linker. This compound is designed for use in PROTAC technology, enabling targeted protein degradation through the ubiquitin-proteasome pathway. It serves as a valuable tool for research in cellular signaling, protein regulation, and therapeutic development. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-amino-PEG4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate featuring the Pomalidomide-derived cereblon ligand. This compound incorporates a PEG4 linker, facilitating effective biomolecular interactions in PROTAC (Proteolysis Targeting Chimeras) technology. It enables targeted protein degradation, making it valuable for research applications in drug discovery and the study of protein homeostasis. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-C5-azide is a ligand-linker conjugate targeting the E3 ubiquitin ligase cereblon (CRBN). The azide moiety facilitates click chemistry, enabling the formation of covalent bonds with other bioactive molecules. This compound is suitable for research applications in protein degradation and targeted therapy development, particularly in the study of immunomodulatory effects and cellular signaling pathways. -
E3 Ligase Ligand-Linker Conjugate
E3 ligase Ligand PG-piperidine-acetaldehyde is an E3 ligase ligand-linker conjugate featuring a CRBN-based ligand. This compound is instrumental in the synthesis of proteolysis-targeting chimeras (PROTACs), facilitating targeted protein degradation. It serves as a valuable tool for research applications aimed at modulating protein levels in various biological systems. -
E3 Ligase Ligand-Linker Conjugates
1-Piperazinehexanoic acid-thalidomide functions as an E3 ligase ligand-linker conjugate, essential for the synthesis of complete JMV7048. This compound plays a critical role in the development of targeted protein degradation strategies, facilitating research into therapeutic applications in oncology and other diseases. Its structural properties enable efficient conjugation, advancing the understanding of E3 ligase modulation in biological systems. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-piperidin-4-ylmethanol is an E3 ligase ligand-linker conjugate known for its affinity to cereblon (CRBN). This compound is instrumental in the synthesis of proteolysis-targeting chimeras (PROTACs), facilitating targeted protein degradation. It is valuable for research applications in directed protein modulation and cellular pathway analysis. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-azetidine-C-OH is an E3 ligase ligand-linker conjugate that features a CRBN-based ligand combined with a linker moiety. This compound facilitates the design and synthesis of PROTACs, which are innovative bifunctional molecules capable of targeting and ubiquitinating specific proteins for degradation. With its potential applications in targeted protein degradation studies, Thalidomide-azetidine-C-OH serves as a valuable tool for researchers investigating cellular signaling pathways and protein homeostasis. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-piperazine hydrochloride is an E3 ligase ligand-linker conjugate that incorporates a Cereblon (CRBN)-based ligand along with a piperazine linker. This compound is instrumental in the synthesis of Proteolysis Targeting Chimeras (PROTACs), facilitating targeted protein degradation. It plays a critical role in advancing research on targeted therapies for various cancers and other diseases by modulating protein levels within cellular environments. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide 4'-alkylC3-azide is an E3 ligase ligand-linker conjugate designed for use with cereblon (CRBN). This compound facilitates the development of proteolysis-targeting chimeras (PROTACs) by linking E3 ligase activity to targeted protein degradation. It is valuable for research applications in cellular signaling and therapeutic development, enabling innovative strategies in targeted protein modulation. -
E3 Ligase Ligand-Linker Conjugate
(S)-Glutarimide-amide-Py-piperidine-CHO is an E3 ligase ligand-linker conjugate designed to engage cereblon (CRBN). This compound facilitates the formation of PROTAC molecules, enabling targeted protein degradation in cellular systems. Its utility in biochemistry offers potential for applications in drug development and therapeutic research focused on modulating protein levels within the cell. -
E3 Ligase Ligand-Linker Conjugate
(3S)Lenalidomide-5-methylpiperazine benzenesulfonate is an E3 ligase ligand-linker conjugate that incorporates a cereblon (CRBN)-based ligand. This compound serves as a crucial building block for the synthesis of proteolysis-targeting chimeras (PROTACs), which enable targeted protein degradation. It is instrumental in research applications focused on modulating protein levels and investigating cellular pathways associated with diseases such as cancer. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-acetylene-C2-NH2 is an E3 ligase ligand-linker conjugate designed to engage cereblon (CRBN) for targeted protein degradation. This compound serves as a crucial component for the synthesis of proteolysis-targeting chimeras (PROTACs), facilitating the selective degradation of proteins by the ubiquitin-proteasome system. Its unique structure enables researchers to explore novel therapeutic strategies and efficacy in various biological contexts. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-C2-COOH is an E3 ligase ligand-linker conjugate that features a cereblon (CRBN)-based ligand and a flexible linker. This compound is designed for use in the synthesis of PROTACs (proteolysis-targeting chimeras), enabling targeted protein degradation. Its capacity to engage E3 ligases makes it a valuable tool for research in cellular protein regulation and therapeutic targeted intervention. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-C10-NH2 is an E3 ligase ligand-linker conjugate designed to facilitate targeted protein degradation. This compound integrates the (S,R,S)-AHPC-derived VHL ligand with a robust linker, promoting the formation of BET-targeted PROTACs. It serves as an essential tool for researchers investigating ubiquitin-proteasome system pathways and advancing therapeutic strategies through targeted protein modulation. -
E3 Ligase Ligand-Linker Conjugates
Lenalidomide-PEG3-iodine is an E3 ligase ligand-linker conjugate that combines a Lenalidomide-derived cereblon ligand with a three-unit polyethylene glycol (PEG) linker. This compound facilitates the synthesis of proteolysis-targeting chimeras (PROTACs), including the potent BTK degrader SJF620, which demonstrates a DC50 of 7.9 nM. Lenalidomide-PEG3-iodine is valuable for research in targeted protein degradation and the development of innovative therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-C6-NH2 dihydrochloride is an E3 ligase ligand-linker conjugate that combines the VHL ligand derived from VH032 with a C6 linker, specifically designed for the development of AKT PROTAC degraders. This compound facilitates targeted protein degradation by recruiting E3 ligases, thereby offering significant utility in studies of protein turnover and cellular signaling pathways. It serves as a valuable tool for researchers investigating the effects of synthetic PROTACs in therapeutic contexts. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-C8-NH2 dihydrochloride is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound incorporates the VH032-derived VHL ligand, facilitating the recruitment of E3 ligases for degradation of target proteins. Its linker is specifically optimized for use in AKT PROTACs, making it valuable for research in protein degradation pathways and therapeutic development. This compound is referenced as XF038-164A, example 8, and is derived from patent WO2019173516A1. -
E3 Ligase Ligand-linker Conjugate
(S,R,S)-AHPC-C3-NH2 TFA is an E3 ligase ligand-linker conjugate designed for use in proteolysis-targeted chimera (PROTAC) technology. This compound features the VH032-derived VHL ligand, facilitating targeted degradation of specific substrates. It is instrumental in synthesizing various PROTACs, including UNC6852, which targets EED for bivalent degradation, making it valuable for studies in cellular regulation and protein homeostasis. -
E3 Ligase Ligand-Linker Conjugates
Lenalidomide-C5-NH2 TFA is an E3 ligase ligand-linker conjugate that targets the Cereblon (CRBN) protein. This compound facilitates the recruitment of CRBN, enabling the development of PROTACs for targeted protein degradation applications, including MDM2 PROTAC degraders. Its ability to link specific ligands for protein degradation makes it a valuable tool in chemical biology and therapeutic development research. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-C10-NH2 dihydrochloride is a specialized E3 ligase ligand-linker conjugate, incorporating the (S,R,S)-AHPC-derived VHL ligand. This compound functions as a key component in the development of BET-targeted PROTACs, facilitating targeted protein degradation in cellular systems. Its application in chemical biology allows for the exploration of protein function through enhanced specificity for E3 ligase engagement, making it a valuable reagent for researchers investigating protein modulation mechanisms. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-PEG1-NH2 dihydrochloride is an E3 ligase ligand-linker conjugate featuring a VHL ligand designed for the ubiquitin-proteasome system, combined with a PROTAC linker. This compound is instrumental in the development of PROTACs, facilitating targeted protein degradation and elucidating cellular processes. Its utility extends to studies exploring protein interactions and degradation pathways, making it a valuable tool in chemical biology and drug discovery research. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-amido-PEG4-C2-NH2 is an engineered E3 ligase ligand-linker conjugate that features a thalidomide-derived cereblon ligand combined with a PEG4 linker. This compound is designed to facilitate targeted protein degradation via PROTAC (Proteolysis Targeting Chimera) technology, enabling the selective modulation of protein levels in cellular systems. Its applications include studying protein degradation pathways and developing therapeutic strategies that leverage the ubiquitin-proteasome system for enhanced drug efficacy. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-PEG2-Tos is an E3 ligase ligand-linker conjugate that incorporates a cereblon ligand connected through a diethylene glycol (PEG2) spacer. This compound facilitates targeted protein degradation by recruiting E3 ligases, enabling the selective degradation of specific substrates. It is especially useful in research focused on the modulation of protein levels and the development of targeted therapeutics for various diseases, including cancer. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-C4-NH2 is an engineered E3 ligase ligand-linker conjugate that features the (S,R,S)-AHPC-based von Hippel-Lindau (VHL) ligand. This compound is designed to facilitate the development of EED-targeted PROTACs by promoting the ubiquitination and subsequent degradation of specific protein targets. Its ability to selectively engage E3 ligases makes it a valuable tool for probing protein turnover and elucidating the dynamics of cellular signaling pathways. -
E3 Ligase Ligand-Linker Lonjugate
(S,R,S)-AHPC-O-Ph-PEG1-NH-Boc is an E3 ligase ligand-linker conjugate designed to facilitate targeted protein degradation through the EED pathway. This compound effectively engages E3 ligases, enabling the development of PROTACs (proteolysis-targeting chimeras) for precise modulation of protein levels in various biological systems. Its utility spans applications in chemical biology and therapeutic research focused on protein degradation and regulation. -
E3 Ligase Ligand-Linker Conjugates
VHL Ligand-Linker Conjugates 15 functions as an E3 ligase ligand-linker conjugate, incorporating a von Hippel-Lindau (VHL) ligand paired with a PROTAC linker. This compound is designed to facilitate the development of PROTACs, enabling targeted protein degradation. Its application spans various areas of research, particularly in therapeutic discovery and cellular regulation studies where modulation of protein levels is essential. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-Me-C10-NH2 is a synthesized conjugate designed for E3 ligase targeting, incorporating a von Hippel-Lindau (VHL) ligand and a linker. This compound serves as a key component in creating proteolysis-targeting chimeras (PROTACs), facilitating the selective degradation of intracellular proteins. Its application in research can help elucidate the roles of specific proteins in various biological processes and disease pathways. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-amido-C4-amido-C6-NH-Boc is a synthesized E3 ligase ligand-linker conjugate that employs the Pomalidomide-derived cereblon ligand for targeted protein degradation. This compound is designed to enhance the specificity and efficacy of PROTAC (Proteolysis Targeting Chimera) technology, facilitating the targeted ubiquitination and subsequent degradation of selected proteins. Its applications include investigating cellular pathways and therapeutic strategies in various diseases, including cancer. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-amido-C4-amido-PEG2-C2-NH-Boc is an E3 ligase ligand-linker conjugate that features a Pomalidomide-derived cereblon ligand combined with a two-unit polyethylene glycol (PEG) linker. This compound is designed for use in PROTAC (Proteolysis Targeting Chimeras) technology, facilitating targeted protein degradation. Its structure enhances molecular stability and solubility, making it suitable for research applications focused on protein regulation and therapeutic development. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-C6-O-C5-O-C4-COOH is an E3 ligase ligand-linker conjugate designed to engage cereblon via its Pomalidomide moiety. This compound serves as a versatile tool for the synthesis of PROTACs (Proteolysis Targeting Chimeras), facilitating targeted protein degradation in various biological research applications. Its unique structural features enhance its potential for specific ligand binding and effectiveness in manipulating cellular protein levels, making it suitable for investigations into protein regulation and therapeutic development. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-amino-PEG5-NH2 is a conjugate designed for E3 ligase modulation, utilizing a Pomalidomide-derived ligand targeting cereblon. This compound features a PEG5 linker, facilitating its application in PROTAC technology. It is valuable for studies in targeted protein degradation and related therapeutic strategies. -
E3 Ligase Ligand-linker Conjugate
(S,R,S)-AHPC-Bromooctanoic acid is an E3 ligase ligand-linker conjugate that incorporates (S,R,S)-AHPC and a corresponding linker. This compound functions as a ligand for the von Hippel-Lindau (VHL) protein, facilitating the recruitment of VHL in targeted protein degradation applications. It serves as a crucial intermediate in the synthesis of complete PROTAC (proteolysis targeting chimera) molecules for advanced research into targeted therapeutics and protein modulation. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-C7-amine is an E3 ligase ligand-linker conjugate that combines the VHL ligand VH032 with a specialized linker for enhanced targeting of estrogen-related receptor α (ERRα). This compound is designed for use in the development of PROTAC degraders, allowing for selective degradation of specific proteins through the ubiquitin-proteasome pathway. Its applications extend to studies in targeted protein degradation and the modulation of cellular pathways associated with ERRα. -
MAGL Ligand-Linker Conjugate
MAGL Ligand-Linker Conjugate 1 is a conjugate designed to target monoacylglycerol lipase (MAGL) through its ligand-linker structure. This reagent serves as an essential component for the synthesis of PROTAC MAGL degrader-1, facilitating targeted protein degradation in research applications focused on MAGL inhibition. Its utility extends to studies involving lipid metabolism and related signaling pathways. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-NHCO-C-O-C5-N3 is a conjugate designed for E3 ligase applications, integrating a specific ligand with a useful linker. This compound is instrumental in the synthesis of PROTACs, particularly for the targeted degradation of SARS-CoV-2 Mpro, enabling innovative research into viral protein regulation. Its utility in complex molecular biology studies makes it a valuable tool for advancing therapeutic development strategies.
